N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties

Urea transporters (UTs) have been identified as new targets for diuretics. Functional deletion of UTs led to urea-selective urinary concentrating defects with relative salt sparing. In our previous study, a UT inhibitor with a diarylamide scaffold, which is denoted as 11a, was demonstrated as the first orally available UT inhibitor. However, the oral bioavailability of 11a was only 4.38%, which obstructed its clinical application. In this work, by replacing the nitro group of Ha with an acetyl group, 25a was obtained. Compared with 11a, 25a showed a 10 times stronger inhibitory effect on UT-B (0.14 mu M vs. 1.41 mu M in rats, and 0.48 mu M vs. 5.82 mu M in mice) and a much higher inhibition rate on UT-Al. Moreover, the metabolic stability both in vitro and in vivo and the drug-like properties (permeability and solubility) of 25a were obviously improved compared with those of 11a. Moreover, the bioavailability of 25a was 15.18%, which was 3 times higher than that of 11a, thereby resulting in significant enhancement of the diuretic activities in rats and mice. 25a showed excellent potential for development as a promising clinical diuretic candidate for targeting UTs to treat diseases that require long-term usage of diuretics, such as hyponatremia. (C) 2021 Published by Elsevier Masson SAS.

Automated summary

By replacing the nitro group of 11a with an acetyl group, a new UT inhibitor, 25a, was developed with significantly improved inhibitory effects on UT-B and UT-A1 in rats and mice. The metabolic stability, drug-like properties, and bioavailability of 25a were substantially enhanced compared to 11a, leading to significant improvement in diuretic activities in animal models.